Thin
1 / 2
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, a class of drugs that have been clinically proven to be effective in helping individuals manage their weight. By mimicking the effects of the natural hormone GLP-1, semaglutide plays a vital role in regulating appetite and blood sugar levels. This innovative approach not only aids in weight loss, but also improves metabolic health, making it a comprehensive solution for those seeking to change their lifestyle.
Semaglutide is a GLP-1 receptor agonist that regulates blood glucose by stimulating insulin secretion and inhibiting glucagon release. It is commonly used in clinical research for type 2 diabetes management, weight management, and obesity-related studies.
Semaglutide (marketed as Wegovy®/Ozempic®) is administered by once-weekly subcutaneous injection. Common dosing protocols for obesity and weight management range from 0.25 mg up to 2.4 mg weekly, with gradual titration based on tolerance and therapeutic goals. A new higher 7.2 mg weekly dose has been approved in some regions to enhance weight-loss efficacy in clinical settings.
Semaglutide is protected by a broad patent portfolio covering compositions, formulations, and therapeutic uses. Key U.S. patents include:
These extended protections help delay generic competition in major markets such as the U.S. until the late 2030s–early 2040s.
Semaglutide is a GLP-1 receptor agonist that mimics the natural GLP-1 hormone. It regulates appetite and blood sugar levels by stimulating insulin secretion and suppressing glucagon release.
Semaglutide is widely marketed under the commercial brand names Wegovy® and Ozempic® for obesity management and type 2 diabetes treatment.
It is administered via once-weekly subcutaneous injection. Dosing protocols typically start at 0.25 mg and titrate gradually up to 2.4 mg per week depending on individual tolerance and therapeutic goals.
Yes, a new higher dose of 7.2 mg weekly has been approved in certain regions to provide enhanced weight-loss efficacy in specific clinical settings.
Due to extensive patent protections (including US11318191, US11478533, and US12214017/US8129343B2) that extend until 2038–2041, generic competition in major markets like the U.S. is delayed until the late 2030s to early 2040s.
